Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Circulating tumor cells in the bone marrow of patients with metastatic renal cell carcinoma may be prognostic of outcome

Circulating tumor cells in the blood and bone marrow have been examined in a variety of malignancies, including colorectal, breast, and head & neck cancers, to determine their prognostic significance.

8 May 2006

Underutilization of partial nephrectomy for localized renal cell carcinoma in the U.S.

In the past, the gold standard for the treatment of localized renal tumors has been radical nephrectomy. Over time however, experience with nephron sparing surgery and, now, laparoscopic approaches have demonstrated oncologic equipoise and may provide for an improved quality of life for patients as compared to those undergoing radical nephrectomy for localized renal masses.

31 Mar 2006

Thrombocytosis: A clinical marker of tumor aggressiveness in renal cell carcinoma

Molecular and serum markers of prognosis in renal cell carcinoma have remained elusive. In large part, tumor (TNM) stage, Fuhrman grade, and patient performance status have stood the test of time as the most valuable factors in predicting patient outcome following surgery.

15 Mar 2006

Therapy for metastatic renal cell carcinoma remains inadequate

The recent FDA approvals of the tyrosine kinase inhibitors sorafenib and sunitinib based on their activity in metastatic renal cell carcinoma have excited the medical oncology community

9 Mar 2006

Is there any role for thalidomide as a monotherapy in the management of metastatic renal cell carcinoma?

Thalidomide remains an enigma in the treatment of metastatic renal cell carcinoma (RCC). Initial clinical trials suggested a benefit, but more recently, subsequent randomized trials studying thalidomide in combination with other agents such as interferon have demonstrated no added benefit.

8 Mar 2006

Targeted cancer therapies: Another step forward

While it is clear that the treatment of cancer has already begun to undergo a paradigm shift with the inclusion of innovative targeted therapies into current regimens, it would be wrong to assume these products will entirely replace traditional chemotherapy as the standard treatment for cancer sufferers.

22 Dec 2005

Targeted cancer therapies: Another step forward

22 Dec 2005

Imatinib mesylate (Gleevec) may not be effective at treating kidney cancer

Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs), is not likely to be effective for patients with high grade renal cell carcinoma -- the most aggressive kidney cancer.

22 Dec 2005

FDA approval sought for Pfizer's new cancer drug

Drug company Pfizer has announced it has submitted a New Drug Application (NDA) for its cancer drug Sutent, to the U.S. Food and Drug Administration (FDA).

11 Aug 2005

Radiofrequency ablation (RFA) is an effective, longlasting treatment for small kidney tumors in selected patients

Massachusetts General Hospital (MGH) researchers have shown that radiofrequency ablation (RFA) - a minimally invasive way of destroying tissue - is an effective, longlasting treatment for small kidney tumors in selected patients.

20 Jun 2005

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Recent studies of a new anticancer drug show continued response for patients with late-stage kidney cancer. Robert Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), reported a response rate of 40 percent in patients with metastatic (advanced) renal cell (kidney) cancer who received SU11248 in second-line therapy.

15 May 2005

Avastin available across Europe within the next few weeks

Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer.

16 Jan 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005

Key molecule helps identify renal cell carcinoma

Mayo Clinic researchers have discovered a key molecule that lets doctors identify one of the most aggressive types of kidney cancer. Patients with renal cell carcinoma who have higher levels of a molecule known as B7-H1 in their tumors are nearly five times more likely to die from the disease than patients with low levels or an absence of the molecule.

30 Nov 2004

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the Canadian Patent Office entitled "Antitumor Antisense Sequences Directed Against R1 and R2 Components of Ribonucleotide Reductase."

10 Nov 2004

Counseling for breast cancer patients means healthier diets, reduced smoking and stronger immune systems

Regular psychological counseling for breast cancer patients may do more than just lower their stress and anxiety. A new study says the right kind of intervention can also mean healthier diets, reduced smoking, and most surprising of all – a stronger immune system.

2 Sep 2004

FDA fast tracks temsirolimus, first-line treatment of poor-prognosis patients with advanced renal cell carcinoma

Wyeth Pharmaceuticals has announced that the U.S. Food and Drug Administration has granted a new "fast track" designation for temsirolimus (CCI-779), an investigational mTOR kinase inhibitor, in the first-line treatment of poor-prognosis patients with advanced renal cell carcinoma (RCC).

18 Aug 2004

Potential new strategy for blocking tumor growth

Targeting a master molecule that helps cancer cells survive when blood oxygen levels are low may offer a potentially powerful strategy for blocking tumor growth, say researchers at The University of Texas M. D. Anderson Cancer Center.

16 Jun 2004

Drug Tarceva improves survival chance for patients with advanced lung cancer

Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).

5 Jun 2004

Avastin study shows significant improvement in patients with metastatic colorectal cancer

Genentech, Inc. and Roche have announced that the New England Journal of Medicine published the first Phase III study of an anti-angiogenesis cancer therapy, showing that the addition of Avastin™ (bevacizumab) to the IFL chemotherapy regimen (5-FU/Leucovorin/ CPT-11) significantly extended survival in patients with first-line (previously untreated) metastatic colorectal cancer.

2 Jun 2004

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Circulating tumor cells in the bone marrow of patients with metastatic renal cell carcinoma may be prognostic of outcome

Underutilization of partial nephrectomy for localized renal cell carcinoma in the U.S.

Thrombocytosis: A clinical marker of tumor aggressiveness in renal cell carcinoma

Therapy for metastatic renal cell carcinoma remains inadequate

Is there any role for thalidomide as a monotherapy in the management of metastatic renal cell carcinoma?

Targeted cancer therapies: Another step forward

Targeted cancer therapies: Another step forward

Imatinib mesylate (Gleevec) may not be effective at treating kidney cancer

FDA approval sought for Pfizer's new cancer drug

Radiofrequency ablation (RFA) is an effective, longlasting treatment for small kidney tumors in selected patients

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Avastin available across Europe within the next few weeks

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Key molecule helps identify renal cell carcinoma

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

Counseling for breast cancer patients means healthier diets, reduced smoking and stronger immune systems

FDA fast tracks temsirolimus, first-line treatment of poor-prognosis patients with advanced renal cell carcinoma

Potential new strategy for blocking tumor growth

Drug Tarceva improves survival chance for patients with advanced lung cancer

Avastin study shows significant improvement in patients with metastatic colorectal cancer

Free guide - everything about renal proximal tubule cells eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Free guide - everything about renal proximal tubule cells eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in